Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia

Chemotherapy-induced nausea and vomiting (CINV) significantly reduce the life quality of cancer patients. A 5-HT3 receptor antagonist, corticosteroid, and H2-blocker have been used to control moderate nausea and vomit in cancer patients. The exploration of the cost-effectiveness of several antiemeti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ida Dzikriyani, Didik Setiawan
Formato:	article
Lenguaje:	EN
Publicado:	Universitas Ahmad Dahlan 2021
Materias:	a cost-effectiveness analysis breast cancer ondansetron dexamethasone ranitidine Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/f48b8a3eb23a45f08f387cecb2e0b55b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f48b8a3eb23a45f08f387cecb2e0b55b
record_format	dspace
spelling	oai:doaj.org-article:f48b8a3eb23a45f08f387cecb2e0b55b2021-11-17T05:31:21ZCost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia10.12928/pharmaciana.v11i3.176502088-45592477-0256https://doaj.org/article/f48b8a3eb23a45f08f387cecb2e0b55b2021-11-01T00:00:00Zhttp://journal.uad.ac.id/index.php/PHARMACIANA/article/view/17650/pdf_205https://doaj.org/toc/2088-4559https://doaj.org/toc/2477-0256Chemotherapy-induced nausea and vomiting (CINV) significantly reduce the life quality of cancer patients. A 5-HT3 receptor antagonist, corticosteroid, and H2-blocker have been used to control moderate nausea and vomit in cancer patients. The exploration of the cost-effectiveness of several antiemetic combinations in breast cancer patients in Prof. Dr. Margono Soekardjo Hospital, Purwokerto, Indonesia was the aim of this research. Seventy-four Breast cancer patients who have prescribed moderate-emetogenic chemotherapy during the year 2017-1019 were included in this research. There were fifteen patients treated with the combination of ondansetron and dexamethasone (OD). Fourteen patients were treated with the combination of ondansetron and ranitidine (OR). Thirty-five patients were treated using ondansetron, dexamethasone, and ranitidine (ODR) combination. The effectiveness was represented by the absence of acute nausea and vomiting after receiving chemotherapy. The ODR combinations showed the highest effectivity on diminishing nausea and vomiting among breast cancer patients (0.400), followed by the OD combination (0.267) and the OR combination (0.214). However, the ODR combination generates the highest cost (4.6 million rupiahs) compared to other antiemetics combinations. Compared to the combination of ondansetron and dexamethasone, the combination of ODR provides higher ICER (ICER of 13 Million Rupiahs per case prevented) than the combination of OR (ICER of 8.5 million Rupiahs per case prevented). In conclusion, the combination of ondansetron, dexamethasone, and ranitidine generates the highest cost. It also provides the highest effectiveness in preventing nausea and vomiting.Ida Dzikriyani,Didik SetiawanUniversitas Ahmad Dahlanarticlea cost-effectiveness analysisbreast cancerondansetrondexamethasoneranitidinePharmacy and materia medicaRS1-441ENPharmaciana, Vol 11, Iss 3, Pp 330-337 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	a cost-effectiveness analysis breast cancer ondansetron dexamethasone ranitidine Pharmacy and materia medica RS1-441
spellingShingle	a cost-effectiveness analysis breast cancer ondansetron dexamethasone ranitidine Pharmacy and materia medica RS1-441 Ida Dzikriyani, Didik Setiawan Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia
description	Chemotherapy-induced nausea and vomiting (CINV) significantly reduce the life quality of cancer patients. A 5-HT3 receptor antagonist, corticosteroid, and H2-blocker have been used to control moderate nausea and vomit in cancer patients. The exploration of the cost-effectiveness of several antiemetic combinations in breast cancer patients in Prof. Dr. Margono Soekardjo Hospital, Purwokerto, Indonesia was the aim of this research. Seventy-four Breast cancer patients who have prescribed moderate-emetogenic chemotherapy during the year 2017-1019 were included in this research. There were fifteen patients treated with the combination of ondansetron and dexamethasone (OD). Fourteen patients were treated with the combination of ondansetron and ranitidine (OR). Thirty-five patients were treated using ondansetron, dexamethasone, and ranitidine (ODR) combination. The effectiveness was represented by the absence of acute nausea and vomiting after receiving chemotherapy. The ODR combinations showed the highest effectivity on diminishing nausea and vomiting among breast cancer patients (0.400), followed by the OD combination (0.267) and the OR combination (0.214). However, the ODR combination generates the highest cost (4.6 million rupiahs) compared to other antiemetics combinations. Compared to the combination of ondansetron and dexamethasone, the combination of ODR provides higher ICER (ICER of 13 Million Rupiahs per case prevented) than the combination of OR (ICER of 8.5 million Rupiahs per case prevented). In conclusion, the combination of ondansetron, dexamethasone, and ranitidine generates the highest cost. It also provides the highest effectiveness in preventing nausea and vomiting.
format	article
author	Ida Dzikriyani, Didik Setiawan
author_facet	Ida Dzikriyani, Didik Setiawan
author_sort	Ida Dzikriyani,
title	Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia
title_short	Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia
title_full	Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia
title_fullStr	Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia
title_full_unstemmed	Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia
title_sort	cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in prof. dr. margono soekarjo hospital, indonesia
publisher	Universitas Ahmad Dahlan
publishDate	2021
url	https://doaj.org/article/f48b8a3eb23a45f08f387cecb2e0b55b
work_keys_str_mv	AT idadzikriyani costeffectivenessanalysisofantiemeticstherapyinbreastcancerpatientswithmoderateemetogenicchemotherapyinprofdrmargonosoekarjohospitalindonesia AT didiksetiawan costeffectivenessanalysisofantiemeticstherapyinbreastcancerpatientswithmoderateemetogenicchemotherapyinprofdrmargonosoekarjohospitalindonesia
_version_	1718425901597720576

Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia

Ejemplares similares